Protagonist Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. We have successfully utilized this platform to discover PN-943 and PTG-200 which are oral, GI-restricted peptides for inflammatory bowel diseases (IBD), as well as PTG-300, an injectable peptide for rare blood disorders.